FORMULATION AND EVALUATION OF MAGISTRAL TOPICAL CREAM AND LOTION CONTAINING CANNABIDIOL FOR USE IN RHEUMATOID ARTHRITIS
Keywords:
cannabidiol, magistral preparation, topical formulation, rheumatoid arthritisAbstract
When proprietary medicinal products are no longer available in pharmacies, the compounding of topical individual formulations may represent an effective alternative solution. Specific circumstances, such as rare indications, pediatric use, or intolerance to certain ingredients, often create challenges related to the availability, dosage, and selection of appropriate pharmaceutical formulations. In such cases, magistral preparations provide flexibility and enable personalized therapy tailored to individual patient needs. Prepared magistral formulations can be as effective as proprietary or generic medicinal products while maintaining comparable quality standards. In addition, they allow adaptation of the formulation composition and are often more economically accessible. In many situations, magistral preparations remain the only viable therapeutic option when a medicinal product is unavailable on the market. Cannabis has been used as a medicinal plant for millennia; however, systematic scientific investigations of its main components began in the 1960s. Since then, extensive research has been conducted on cannabinoids and their biological activity. In countries where medicinal cannabis use is approved, strict regulations govern its clinical application. One method of administration is through magistral preparations prescribed by a physician and prepared in facilities that meet quality standards, ensuring controlled levels of tetrahydrocannabinol (THC) and cannabidiol (CBD). The aim of this study was the characterization and evaluation of two topical formulations, a cream and a lotion, containing cannabis oil at a concentration of 10%. The primary objective was the selection of suitable bases according to the solubility of the active substance in order to ensure successful formulation. The prepared formulations were evaluated based on appearance, color, identification, pH value, spreadability, cannabidiol content, viscosity, relative density, and microbiological purity. The obtained results demonstrated satisfactory physicochemical characteristics and compliance with pharmacopoeial requirements, indicating appropriate quality and stability of the formulations. Furthermore, the topical dosage forms showed favorable technological properties relevant for routine pharmaceutical compounding and patient use. The study highlights the importance of appropriate excipient selection and formulation design for achieving consistent quality in magistral preparations. Overall, the findings support the potential role of magistral topical cannabis-based preparations as a complementary therapeutic option in pharmaceutical practice and warrant further investigation of their clinical applicability.
References
Alkilani, A. Z., McCrudden, M. T. C., & Donnelly, R. F. (2015). Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics, 7(4), 438–470.
Arthritis Foundation. (2021). Cannabidiol (CBD) and arthritis pain. Arthritis Foundation Scientific Report.
Benson, H. A. E., Watkinson, A. C., & Roberts, M. S. (2019). Topical and transdermal drug delivery: Principles and practice. Wiley-Blackwell.
Bawa, Z., et al. (2024). An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Scientific Reports.
EMA. (2019). Cannabis for medical use: Scientific considerations. European Medicines Agency.
European Pharmacopoeia Commission. (2023). European Pharmacopoeia (11th ed.). Strasbourg: Council of Europe.
FDA. (2020). Cannabidiol (CBD): What we know and what we don’t. U.S. Food and Drug Administration.
Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., … Lichtman, A. H. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain, 20(6), 936–948.
Jurka, T., et al. (2020). Selection of excipients for dermal and transdermal drug delivery systems. International Journal of Pharmaceutics, 586, 119580.
Lapteva, M., Mignani, S., Malyukin, A., & Majoral, J. P. (2024). Cutaneous delivery and biodistribution of cannabidiol in aqueous formulations developed for targeted local treatment of dermatological conditions. Pharmaceutics, 16(2), 202.
Lodzki, M., Godin, B., Rakou, L., Mechoulam, R., Gallily, R., & Touitou, E. (2003). Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model. Journal of Controlled Release, 93(3), 377–387.
Mechoulam, R., Peters, M., Murillo-Rodriguez, E., & Hanus, L. O. (2007). Cannabidiol—recent advances. Chemistry & Biodiversity, 4(8), 1678–1692.
Nagy, G., Roodenrijs, N. M. T., Welsing, P. M. J., Kedves, M., Hamar, A., van der Goes, M. C., Rauch, A., & van Laar, J. M. (2022). EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 81(1), 20–33.
Perucca, E., & Bialer, M. (2020). Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination. Epilepsia, 61(6), 1045–1058.
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215.
Philpott, H. T., O’Brien, M., & McDougall, J. J. (2017). Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain, 158(12), 2442–2451.
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., … Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, 175, 133–150.
Roberts, M. S., Cross, S. E., & Pellett, M. A. (2002). Skin transport. In Dermatological and transdermal formulations. Marcel Dekker.
Scholfield, C. N., et al. (2023). Systematic review on transdermal/topical cannabidiol: Efficacy and safety for skin-applied formulations containing CBD. Cannabis and Cannabinoid Research.
